THE NEW INDUSTRIAL REVOLUTION

Is Nano

HOW NANOGAMI IS REVOLUTIONIZING HEALTH CARE (AND MORE)

THE INNOVATION: SUPER­FUNCTIONAL, PRECISELY PROGRAMMABLE NANOSTRUCTURES

Sprind And Nanogami Why We Are Committed

By leveraging DNA origami, we have the opportunity to become a leader in a key technology in Germany. The potential for this technology is vast and we are committed to igniting an industrial revolution on the nanoscale through its development and application.

What We Do

Our goal is to turn the research project into a successful company. With the help of SPRIND's extensive expert network, we can connect with the right partners and bring together top talent for the project. We have a clear plan in place to guide the development of this technology over the next five years.

Creating Market Focus

Our goal is to create market focus for this technology by identifying the most promising applications, starting with molecular diagnostics and expanding to more complex areas. We are committed to making this project marketable and bringing its benefits to a wider audience.

Providing Resources In The Form Of Budgets And Experts

Also, providing human resources for an LLC: an innovation manager and project manager who take on specific management responsibilities.

THE POTENTIAL WE SEE True opening up of the nano-sector.

“To better understand the potential of DNA nanostructures, we must look at the past and present,” said Dr. Jean-Philippe Sobczak, CSO of Nanogami. In fact, we must go back quite far in history. For the past 50 years, there has been a trend towards more precise diagnoses of illnesses through molecular diagnostics. Antigen tests, which have become a common part of daily life for many people, are an example of this. These tests determine whether a molecule, or antigen, is present in the body to diagnose an illness.

According to Sobczak, this type of testing is “already advanced, but still relatively straightforward.” In reality, we would like to be able to analyze a large number of molecules at the same time. We want to know which molecules are present and in what quantities. To do this, we need highthroughput technology. Biochips, for example, can enable high-throughput molecular diagnostics. A biochip contains patient samples with many different molecules, and it can be inserted into a reader that can simultaneously read billions of sensors on the biochip. This allows us to determine which molecules are present and which are not, as well as whether or not a patient is infected or sick. Current biochip technology for molecular diagnostics can already provide a lot of information—much more than was possible 50 or even 20 years ago. However, it is still not enough, and it is not fast or cost-effective enough.

Jean-Philippe Sobczak continued, “If you go to the doctor today and give a blood sample to determine the quantities of various substances in your blood, it must first be sent to a laboratory. There, it is processed by trained personnel using very expensive readers. The data is then sent back to the doctor, often several days after the sample was taken, and only a small number of molecule types can be analyzed.” Why has all this been so laborintensive until now? Simply put, molecules are very small. The devices or machines used to analyze and assess them—including biochips—are large. Too large. These machines have not been able to, or have only been able to with great difficulty, manipulate individual molecules—such as moving them or marking them. The main problem with diagnosis is that molecules and analysis machines do not match well and are not compatible to a high enough degree.

Nanogami solves this problem with its nanostructures or nanomachines made of DNA. As Sobczak explained, “We design interfaces, or small objects that are large enough to be incorporated into semiconductor chips or other microsystems in a targeted manner, but small enough that we can integrate a socket for the target molecule in a targeted manner.” This is quite ingenious. These ‘ plug structures ’ then assemble themselves, just like biological systems—and they do it in the billions. The innovation is a highly complex, superfunctional nanostructure of the right intermediate size that can be programmed for a specific purpose. This structure is then integrated into something larger, like a biochip. The result is a chip containing billions of extremely small machines that perform highly specific, predefined tasks.

Revolutionizing The Healthcare Market

Sobczak believes that in the near future, everyday diagnoses will be done differently. Instead of sending tissue or fluid samples to a laboratory for evaluation with a multimillion-euro analysis device, people will be able to take care of the task at the physician ’ s office or even at home. It will be faster, cheaper, more detailed, and more precise. It is no surprise that Nanogami is attracting significant interest from life science and pharmaceutical companies that carry out complex molecular diagnostics. These sectors have long been searching for solutions to single-molecule processing to better understand the protein composition of tissue and bodily fluids, for example. For Sobczak, it is clear that using nano-based molecular diagnosis will enable truly customized therapies. Soon, highly personalized and individualized information will be identifiable in diagnoses, making precisely tailored therapies possible. Jean-Philippe Sobczak calls this ‘personalized medicine,’ and he believes that ‘we are already very close.’

A TEAM OF NANO­INSIDERS

Nanogami is a SPRIND subsidiary founded in 2022. It is based on cooperation with tilibit, which was founded by Jean-Philippe Sobczak and Prof. Dr. Hendrik Dietz, an expert in biomolecular nanotechnology who serves as a scientific consultant for ilibit and Nanogami. Initially, tilibit GmbH only provided services to a few universities and organizations that needed DNA nanostructures. However, it soon became clear that tilibit had much more to offer, and their ideas and solutions were of great interest to many customers and players in various markets. This is why Jean-Philippe Sobczak has been working exclusively on the perfection and commercialization of nanotechnology with a carefully selected multidisciplinary team since 2019. With the support of SPRIND, this development is now being taken to the next level with Nanogami.

This team of nano-insiders has many plans for the coming years. Sobczak describes it as sober vision. “Our plan is simply to begin.” The initial focus will be on using nano-machines to manipulate individual molecules and integrate them into specific locations on biochips in a targeted manner. “We will become more and more multifaceted,” he says. The next step specifically is to build nano-machines and biochips that are functionally more complex and then couple them with computer chips. If nano-machines can be coupled with digital chips, many amazing things will be possible. This will enable tilibit to revolutionize other markets and areas of life, such as data storage, the creation of quantum computers, or air pollutant monitoring. The potential of nano is enormous.

» THIS TECHNOLOGY OPENS UP NEW POSSIBILITIES, SUCH AS BUILDING NANOSCALE MACHINES WITH COMPLEX FUNCTIONS, CREATING TOOLS, AND DESIGNING POTENTIAL TINY PRODUCTION LINES. IT REPRESENTS A SIGNIFICANT ADVANCEMENT IN THE FIELD. «